Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. (12th March 2014)

• Record Type: Journal Article
• Authors: Szwiec, M.; Jakubowska, A.; Górski, B.; Huzarski, T.; Tomiczek‐Szwiec, J.; Gronwald, J.; Dębniak, T.; Byrski, T.; Kluźniak, W.; Wokołorczyk, D.; Birkenfeld, B.; Akbari, M.R.; Narod, S.A.; Lubiński, J.; Cybulski, C.
• Is Part Of: Clinical genetics. Volume 87:Number 3(2015:Mar.)
• Page Start: 288
• Page End: 292
• Publication Date: 2014-03-12
• Subjects: Medical genetics -- Periodicals; 616.0420
• DOI: 10.1111/cge.12360
• Languages: English
• ISSNs: 0009-9163

Abstract

<abstract abstract-type="main" id="cge12360-abs-0001"> <title>Abstract</title> <p id="cge12360-para-0001">Three founder alleles of BRCA1 (C61G, 4153delA, 5382insC) were reported in Poland in 2000, and these three mutations have comprised the standard testing panel used throughout the country. However, since 2000, other recurrent mutations of BRCA1 and BRCA2 have been reported. To establish if the inclusion of one or more of these mutations will increase the sensitivity of the standard test panel, we studied 1164 Polish women with unselected breast cancer diagnosed at age of 50 or below. All women were genotyped for 12 recurrent mutations of BRCA1 and BRCA2. We identified a mutation in 83 of 1164 patients (7.1%) including 61 women with one of the original three mutations (C61G, 4153delA, 5382insC) and 22 women with a different mutation (1.9%). Three new mutations (3819del5, 185delAG and 5370C&gt;T) were seen in multiple families. By including these three mutations in the extended panel, the mutant frequency increased from 5.2 to 6.7%. Polish women with breast cancer diagnosed at age of 50 or below should be screened with a panel of six founder mutations of BRCA1 (C61G, 4153delA, 5382insC, 3819del5, 185delAG and 5370C&gt;T).</p> </abstract>